TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07213609: A Phase 1/2 Open-label, Multicenter Study of Oral GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) So

Sponsor: GlaxoSmithKline · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 47 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT07213609 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07213609 Rescue Dossier →